Edwards Lifesciences (EW) Projected to Announce Earnings on Thursday

Edwards Lifesciences (NYSE:EW) is expected to post its Q2 2026 results after the market closes on Thursday, July 23rd. Analysts expect the company to post earnings of $0.73 per share and revenue of $1.7003 billion for the quarter. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 23, 2026 at 5:00 PM ET.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.64 earnings per share. On average, analysts expect Edwards Lifesciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $87.22 on Thursday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The company has a market cap of $50.22 billion, a PE ratio of 46.39, a PEG ratio of 2.26 and a beta of 0.86. The business’s fifty day simple moving average is $87.12 and its 200-day simple moving average is $83.92. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $96.29.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on EW. Evercore restated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Royal Bank Of Canada lifted their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday. Robert W. Baird upped their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Citigroup upped their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Finally, Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a report on Wednesday, April 1st. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $98.73.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,577 shares of company stock valued at $3,855,527 in the last ninety days. 0.31% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Kemnay Advisory Services Inc. purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $27,000. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter worth $25,000. Rakuten Securities Inc. increased its holdings in Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares in the last quarter. Kelleher Financial Advisors purchased a new stake in Edwards Lifesciences in the 3rd quarter worth $50,000. Finally, Chapman Financial Group LLC acquired a new position in Edwards Lifesciences during the second quarter worth $63,000. 79.46% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.